Eli Lilly, a major pharmaceutical company, has seen revenue growth driven by its weight loss drug portfolio. The company sells tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss. Doctors have prescribed these injectables for weight control.
Lilly recently submitted an oral weight loss candidate to regulators for review. If approved, it would add a third product to this portfolio. A weight loss pill offers advantages in convenience and production cost compared to injectable formats.
In the most recent period, Lilly's weight loss drugs helped revenue increase more than 50%. Mounjaro and Zepbound together generated about $10 billion in sales. Sustained demand for weight loss drugs suggests continued growth potential.
Intuitive Surgical is the world's leader in robotic surgery. The company maintains a strong position through surgeon training on its Da Vinci system and hospital investments of $1 million or more per system.
The installed base of systems, number of procedures performed, and revenue have increased over time. Each Da Vinci system represents a source of recurrent revenue through maintenance services, instruments, and accessories. Accessories and instruments make up the majority of Intuitive's quarterly revenue.
Vertex Pharmaceuticals is the world's leading maker of treatments for cystic fibrosis. This has led to gains in earnings and stock price in recent years. The company's intellectual property protects its CF position through the end of the next decade.
Vertex's CF drugs deliver billions of dollars in revenue each year. In the most recent quarter, the company reported revenue of more than $3 billion and expects as much as $12 billion for the full year.
The company has broadened into other areas, generating additional growth. Casgevy for blood disorders surpassed $100 million in revenue last year. Prescriptions for its new pain medicine, Journavx, are expected to triple this year after doctors wrote about half a million prescriptions last year.
The Motley Fool Stock Advisor analyst team identified 10 best stocks for investors to buy now, and Eli Lilly was not among them. The 10 selected stocks could produce significant returns in coming years.
Stock Advisor's total average return is 970%, compared to 197% for the S&P 500. The service provides access to investment recommendations and a community for individual investors.